文献速递眼底病与葡萄膜炎

地图样萎缩从首次诊断到生命终点的扩大过程

Enlargement of Geographic Atrophy From First Diagnosis to End of Life.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

本研究基于4项人群队列(Rotterdam研究1-3及Blue Mountains眼研究),纳入171例地图样萎缩(GA)患者、242只眼,随访至多25年。GA平均扩大速率为1.09 mm²/年(95%CI 0.89-1.30),个体差异大(0.02-4.05 mm²/年)。首次诊断时37.4%的患眼已累及中心凹,未累及者平均5.6年后累及;70.8%患者平均6.4年后死亡。

要点

  • GA平均扩大速率为1.09 mm²/年,但个体间差异极大(0.02-4.05 mm²/年)。
  • 首次诊断时37.4%患眼已累及中心凹,未累及者平均5.6年后累及。
  • 70.8%患者平均6.4年后死亡,末次访视时43.9%患者视力低于20/63。

核心结论

  • 在一般人群中,地图样萎缩(GA)的扩大速率高度可变。
  • 超过三分之一的初发GA在首次呈现时已累及中心凹,中心凹外GA平均5.6年后累及中心凹。
  • 未来干预试验应聚焦于在预期寿命内很可能出现严重视力下降的患者。

研究设计与样本

  • 研究数据来自4项基于人群的队列研究:Rotterdam研究队列1、2、3和Blue Mountains眼研究。
  • 随访至多25年,每5年进行一次眼科检查,数据收集于1990年至2015年,分析于2019年1月至2020年11月。
  • 纳入171例患者(242只眼),其中106例(62.0%)为女性,纳入时平均(SD)年龄为82.6(7.1)岁。
  • 242只眼中147只(60.7%)的GA为本研究新诊断。

主要发现

  • GA首次呈现时平均面积为3.74 mm²(95%CI 3.11-4.67)。
  • GA扩大速率因人而异(0.02至4.05 mm²/年),平均为1.09 mm²/年(95%CI 0.89-1.30)。
  • 对侧眼AMD分期与GA扩大相关(Spearman ρ=0.34;P=.01)。
  • 初发GA中55/147只眼(37.4%)已累及中心凹;42只眼中23只(55%)在平均(范围)5.6(3-12)年后累及中心凹,11/42只眼(26%)至死未累及中心凹。
  • 首次诊断后,171例患者中121例(70.8%)在平均(SD)6.4(5.4)年后死亡;末次访视时107例患者中47例(43.9%)视力低于20/63。

临床怎么用

  • 临床中应认识到GA扩大速率个体差异大,需个体化评估进展风险。
  • 初诊时需注意约三分之一患眼已累及中心凹,未累及者应密切随访中心凹受累情况。
  • 考虑到患者预期寿命和视力下降风险,干预试验应优先招募高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatments for geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), are currently under development. Understanding the natural course is needed for optimal trial design. Although enlargement rates of GA and visual acuity (VA) in the short term are known from clinical studies, knowledge of enlargement in the long term, life expectancy, and visual course is lacking. OBJECTIVE: To determine long-term enlargement of GA. DESIGN, SETTING, AND PARTICIPANTS: In this study, participant data were collected from 4 population-based cohort studies, with up to 25 years of follow-up and eye examinations at 5-year intervals: the Rotterdam Study cohorts 1, 2, and 3 and the Blue Mountains Eye Study. Data were collected from 1990 to 2015, and data were analyzed from January 2019 to November 2020. MAIN OUTCOMES AND MEASURES: Area of GA was measured pixel by pixel using all available imaging. Area enlargement and enlargement of the square root-transformed area, time until GA reached the central fovea, and time until death were assessed, and best-corrected VA, smoking status, macular lesions according to the Three Continent AMD Consortium classification, a modified version of the Wisconsin age-related maculopathy grading system, and AMD genetic variants were covariates in Spearman, Pearson, or Mann-Whitney analyses. RESULTS: Of 171 included patients, 106 (62.0%) were female, and the mean (SD) age at inclusion was 82.6 (7.1) years. A total of 147 of 242 eyes with GA (60.7%) were newly diagnosed in our study. The mean area of GA at first presentation was 3.74 mm2 (95% CI, 3.11-4.67). Enlargement rate varied widely between persons (0.02 to 4.05 mm2 per year), with a mean of 1.09 mm2 per year (95% CI, 0.89-1.30). Stage of AMD in the other eye was correlated with GA enlargement (Spearman ρ = 0.34; P = .01). Foveal involvement was already present in incident GA in 55 of 147 eyes (37.4%); 23 of 42 eyes (55%) developed this after a mean (range) period of 5.6 (3-12) years, and foveal involvement did not develop before death in 11 of 42 eyes (26%). After first diagnosis, 121 of 171 patients with GA (70.8%) died after a mean (SD) period of 6.4 (5.4) years. Visual function was visually impaired (less than 20/63) in 47 of 107 patients (43.9%) at last visit before death. CONCLUSIONS AND RELEVANCE: In this study, enlargement of GA appeared to be highly variable in the general population. More than one-third of incident GA was foveal at first presentation; those with extrafoveal GA developed foveal GA after a mean of 5.6 years. Future intervention trials should focus on recruiting those patients who have a high chance of severe visual decline within their life expectancy.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Colijn JM, Liefers B, Joachim N, et al. Enlargement of Geographic Atrophy From First Diagnosis to End of Life. JAMA Ophthalmol. 2021. PMID: 34014262. doi:10.1001/jamaophthalmol.2021.1407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。